Physician profile
Erol E Verter
NPI 1548610454
$5,441.64
in general payments reported to CMS, 2019-2025
27 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $509 · 2021: $395 · 2022: $511 · 2023: $952 · 2024: $1,848 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,353 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,353.35 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $1,133.13 | 2020-2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $904.95 | 2020-2025 | Eylea Hd, Eylea |
| Abbvie INC. | $434.14 | 2019-2025 | |
| Coherus Oncology, INC. | $329.39 | 2022-2024 | |
| Genentech USA, INC. | $323.75 | 2022-2025 | Vabysmo |
| Alimera Sciences, INC. | $303.31 | 2022-2024 | Iluvien, Yutiq |
| Sandoz INC. | $280.49 | 2024 | Cimerli |
| Alcon Vision LLC | $265.57 | 2019-2022 | |
| Glaukos Corporation | $264.34 | 2019-2020 | |
| Astellas Pharma US INC | $236.48 | 2024 | Izervay |
| Allergan, INC. | $207.78 | 2020-2021 | |
| Genentech, INC. | $143.27 | 2024 | Vabysmo |
| Bausch & Lomb Americas INC. | $100.40 | 2022-2024 | Xipere |
| Novartis Pharmaceuticals Corporation | $99.79 | 2019 | |
| Apellis Pharmaceuticals, INC. | $88.77 | 2022-2024 | Syfovre |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $49.86 | 2023-2025 | Hylenex Recombinant |
| Dutch Ophthalmic, USA | $49.00 | 2024 | Eva, Combined Machine, Tissueblue |
| Janssen Biotech, INC. | $38.25 | 2023-2024 | Simponi, Stelara, Simponi Aria |
| Johnson & Johnson Surgical Vision, INC. | $35.96 | 2025 | Tecnis Iol, Catalys System |
| Ocular Therapeutix, INC. | $30.02 | 2025 | Dextenza |
| Harrow Eye, LLC | $20.87 | 2025 | Iheezo |
| Ani Pharmaceuticals, INC. | $19.74 | 2025 | Yutiq |
| Rayner Intraocular Lenses Limited | $19.30 | 2024 | Rayone Emv, Rayone Spheric, Omidria |
| Oyster Point Pharma, INC. | $16.59 | 2022 | |
| Omeros Corporation | $16.41 | 2021 | |
| Amgen INC. | $16.14 | 2024 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $13.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erol Verter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.